Guillermo Torre-Amione
Methodist DeBakey Heart Center
Baylor College of Medicine
Houston
Texas 77030
USA
Name/email consistency: high
- Immune activation in chronic heart failure. Torre-Amione, G. Am. J. Cardiol. (2005)
- Broad modulation of tissue responses (immune activation) by celacade may favorably influence pathologic processes associated with heart failure progression. Torre-Amione, G., Sestier, F., Radovancevic, B., Young, J. Am. J. Cardiol. (2005)
- Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. Torre-Amione, G., Sestier, F., Radovancevic, B., Young, J. J. Am. Coll. Cardiol. (2004)
- Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. Torre-Amione, G., Young, J.B., Colucci, W.S., Lewis, B.S., Pratt, C., Cotter, G., Stangl, K., Elkayam, U., Teerlink, J.R., Frey, A., Rainisio, M., Kobrin, I. J. Am. Coll. Cardiol. (2003)
- Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Torre-Amione, G., Young, J.B., Durand, J., Bozkurt, B., Mann, D.L., Kobrin, I., Pratt, C.M. Circulation (2001)
- A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure. Torre-Amione, G., Durand, J.B., Nagueh, S., Vooletich, M.T., Kobrin, I., Pratt, C. Chest (2001)